![Alan Parker](https://profiles-cardiff.imgix.net/attachments/2538?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor Alan Parker
Professor of Translational Virotherapies. Head of Section of Solid Cancers, Division of Cancer and Genetics
- ParkerAL@cardiff.ac.uk
- +44 29225 10231
- Henry Wellcome Building for Biomedical Research, Room 3F08, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
- Media commentator
- Available for postgraduate supervision
Overview
I have a long standing interest in virology and how this can be applied to cancer therapies using "oncolytic" adenoviral based vectors ("virotherapy"), that stems back to my PhD (awarded in 2003 from the University of Birmingham.)
Prior to relocating to Cardiff, I was studying adenoviral vectors for translational applications in cardiovascular disease, where my research had pinpointed key virus interactions with host blood coagulation factors (most notably Factor X) that dictate the tropism and toxicity of intravenously administered viral vectors. I relocated to Cardiff University in 2013, driven by a long term ambition to lead a world leading team developing “virotherapies” for treatment of cancer. Immediately following my recruitment, I began to develop a team, which now numbers almost 20. I was promoted to Senior Lecturer in 2014, to Reader in 2018, and to Personal Chair in 2020.
Research within my group focusses on several aspects of adenovirology, with the overarching aim of developing more selective and efficacious virotherapies for translational applications in cancer, namely:
- Defining and genetically precluding dose limiting interactions between virus and host cells, proteins and receptors.
- Developing targeting technologies that efficiently enable adenoviral vectors to infect cancerous cells, leaving "normal" cells non-infected.
- Developing new serotypes of Adenoviral vectors with new and exciting tropisms for translational applications.
I am a registered STEMNet ambassador (http://networking.stemnet.org.uk/user/30519), and passionate about the need to engage with the lay community to convey science. I play a leading role in a range of engagement activities, including presenting at the annual BSGCT public engagement day preceding the annual conference, and also at events “in house” at Cardiff University, where I have featured in several blog articles (e.g. see https://www.bsgct.org/virotherapy-showcased-at-cardiff-cancer-open-day/ and https://www.youtube.com/watch?v=3iZquZ4K5E4). In my role as a STEM ambassador, I regularly attend my local school to engage the students in gene therapy and my role as a scientist, and helped out with mock interviews. My involvement and engagement activities have featured in a School of Medicine Case Study (see https://www.cardiff.ac.uk/medicine/about-us/engagement/case-study-dr-alan-parker). I have also written lay articles for both the BSGCT blog (https://www.bsgct.org/author/alanparker/) and ASGCT educational resources. I am passionate about improving career prospects for early career researchers (ECRs), and as a board member of the British Society for Gene and Cell Therapy, I have established and run a subcommittee devoted to development of Early Career Researchers, as well as updating the BSGCT facebook page (www.facebook.com/BSGCT) and twitter feed (@_BSGCT) as part of my role on the BSGCT communication & promotion subcommittee.
Publication
2023
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Preston, H. E., Bayliss, R., Temperton, N., Neto, M. M., Brewer, J. and Parker, A. L. 2023. Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation. iScience 26(9), article number: 107567. (10.1016/j.isci.2023.107567)
- Lovatt, C. and Parker, A. L. 2023. Oncolytic viruses and immune checkpoint inhibitors: the "hot" new power couple. Cancers 15(16), article number: 4178. (10.3390/cancers15164178)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
- Othman, M. et al. 2023. Corrigendum to To clot or not to clot? Ad is the question?Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia [J Thromb Haemost. 2021 Nov;19(11):2845-2856. doi: 10.1111/jth.15485]. Journal of Thrombosis and Haemostasis (10.1016/j.jtha.2023.01.022)
2022
- Swift, E. A., Pollard, S. M. and Parker, A. L. 2022. Engineering cancer selective virotherapies: are the pieces of the puzzle falling into place?. Human Gene Therapy 33(21-22) (10.1089/hum.2022.178)
- Cunliffe, T. G., Parker, A. L. and Jaramillo, A. 2022. Pseudotyping bacteriophage P2 tail fibers to extend the host range for biomedical applications. ACS Synthetic Biology 11(10), pp. 3207-3215. (10.1021/acssynbio.1c00629)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Toh, C., Wang, G. and Parker, A. L. 2022. The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. Clinical Medicine 22(2), pp. 140-144. (10.7861/clinmed.2022-0006)
2021
- Tate, S. J., Van de Sande, L., Ceelen, W. P., Torkington, J. and Parker, A. L. 2021. The feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to administer oncolytic adenoviruses. Pharmaceutics 13(12), article number: 2043. (10.3390/pharmaceutics13122043)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Othman, M. et al. 2021. To clot or not to clot? Ad is the question - insights on mechanisms related to vaccine induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 19(11), pp. 2845-2856. (10.1111/jth.15485)
- Nestic, D., Bozinovic, K., Pehar, I., Wallace, R., Parker, A. L. and Majhen, D. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Davies, J. A. et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13(5), article number: 864. (10.3390/v13050864)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
2020
- Wongthida, P. et al. 2020. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology 22(12), pp. 1757-1770. (10.1093/neuonc/noaa126)
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
- Mowbray, N. G. et al. 2020. Safe management of surgical smoke in the age of COVID-19. British Journal of Surgery 107(11), pp. 1406-1413. (10.1002/bjs.11679)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- Crowther, M. D. et al. 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21, pp. 178 - 185. (10.1038/s41590-019-0578-8)
2019
- Man, S., Foster, J., Carapuca, E., Davies, J. A., Parker, A., Sosabowski, J. and Hallden, G. 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9, article number: 12840. (10.1038/s41598-019-49150-9)
- Baker, A., Mundy, R. M., Davies, J. A., Rizkallah, P. and Parker, A. L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
- Baker, A. T., Mundy, R., Davies, J., Rizkillah, P. T. and Parker, A. L. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. [Online]. bioRxiv. (10.1101/580076) Available at: https://doi.org/10.1101/580076
- Baker, A. T. et al. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10, article number: 741. (10.1038/s41467-019-08599-y)
2018
- Uusi-Kerttula, H. et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24(17), pp. 4215-4224. (10.1158/1078-0432.CCR-18-1089)
- Baker, A., Aguirre-Hernández, C., Halldén, G. and Parker, A. 2018. Designer oncolytic adenovirus: coming of age. Cancers 10(6), article number: 201. (10.3390/cancers10060201)
- Hulin-Curtis, S., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D. and Parker, A. L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9(41), pp. 26328-26341. (10.18632/oncotarget.25242)
- Man, Y. K. S. et al. 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17(2), pp. 575-587. (10.1158/1535-7163.MCT-17-0671)
- Uusi-Kerttula, H. and Parker, A. L. 2018. Precision virotherapies: Coming soon. Oncotarget 9(86) (10.18632/oncotarget.26280)
2017
- Yan, B., Wang, Z., Parker, A., Lai, Y., Thomas, J. P., Yue, L. and Monks, J. N. 2017. Superlensing microscope objective lens. Applied Optics 56(11), pp. 3142-3147. (10.1364/AO.56.003142)
2016
- Robertson, S., Alba, R., Duffy, M. R., Clarke, C., Parker, A. L., Nicklin, S. A. and Baker, A. H. 2016. Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology 97(8), pp. 1911-1916. (10.1099/jgv.0.000505)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Hanna, L., Chester, J. D. and Parker, A. L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22)
- Uusi-Kerttula, H., Davies, J., Curtis, S., Chester, J. and Parker, A. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545)
2015
- Uusi-Kerttula, H., Hulin-Curtis, S., Davies, J. A. and Parker, A. L. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7(11), pp. 6009-6042. (10.3390/v7112923)
- Uusi-Kerttula, H., Davies, J. A., Coughlan, L., Chester, J. D., Parker, A. L. and Parker, A. L. 2015. Incorporation of avß6 integrin-targeting peptide into chimaeric Ad5/fibre knob 48 vector results in efficient tumour-targeting and evasion of neutralisation in clinical ascites. Human Gene Therapy 26(10), pp. A93-A93., article number: P224. (10.1089/hum.2015.29008.abstracts)
- Uusi-Kerttula, H., Davies, J., Coughlan, L., Jones, R., Chester, J. D. and Parker, A. L. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26(9), pp. A33-A33., article number: PO71. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26(9), pp. A23-A23., article number: PO39. (10.1089/hum.2015.29005.abstracts)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Baker, A., Chester, J. D. and Parker, A. L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34., article number: PO72. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015)
- Dakin, R. S., Parker, A. L., Delles, C., Nicklin, S. A. and Baker, A. H. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy 26(5), pp. 312-319. (10.1089/hum.2015.019)
- Nivsarkar, M. S. et al. 2015. Evidence for contribution of CD4+CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery. Journal of Immunology Research 2015, article number: 397879. (10.1155/2015/397879)
2014
- Guinn, B., Braidwood, L., Parker, A., Peng, K. and Seymour, L. 2014. 8th international conference on oncolytic virus therapeutics. Human Gene Therapy 25(12), pp. 1062-1084. (10.1089/hum.2014.118)
- Dakin, R. S., Parker, A., Ma, J., Custers, J., Nicklin, S. A. and Baker, A. H. 2014. Efficient gene transfer to human vascular cells in vitro and ex vivo using adenovirus serotype 49. Cardiovascular Research 103(suppl), pp. S42. (10.1093/cvr/cvu082.170)
- Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L. and Baker, A. H. 2014. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy 25(4), pp. 385-394. (10.1089/hum.2014.016)
2013
- Parker, A. L., Bradshaw, A. C., Alba, R., Nicklin, S. A. and Baker, A. H. 2013. Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. eds. Adenovirus., Vol. 1089. Methods in Molecular Biology Humana Press, pp. 45-59., (10.1007/978-1-62703-679-5_3)
- Parker, A. L., White, K. M., Lavery, C. A., Custers, J., Waddington, S. N. and Baker, A. H. 2013. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy 20(12), pp. 1158-1164. (10.1038/gt.2013.44)
- White, K. M. et al. 2013. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery 8(1), article number: 183. (10.1186/1749-8090-8-183)
- Kaur, H., Toukh, M., Corscadden, K., Parker, A. L. and Othman, M. 2013. Fucoidan improves adenovirus mediated thrombocytopenia and enhances viral liver transduction [Abstract]. Journal of Thrombosis and Haemostatis 11(S1), pp. 451-452. (10.1111/jth.12284)
- Duffy, M. R., Parker, A. L., Kalkman, E. R., White, K., Kovalskyy, D., Kelly, S. M. and Baker, A. H. 2013. Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release 170(1), pp. 132-140. (10.1016/j.jconrel.2013.05.007)
2012
- Coughlan, L. et al. 2012. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy 20(12), pp. 2268-2281. (10.1038/mt.2012.162)
- Duffy, M. R., Parker, A. L., Bradshaw, A. C. and Baker, A. H. 2012. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine 7(2), pp. 271-288. (10.2217/nnm.11.186)
2011
- Coughlan, L., Uusi-Kerttula, H., Degg, B., Parker, A. L., Custers, J., Nicklin, S. A. and Baker, A. H. 2011. In vitro assessment of targeting peptide incorporation within the knob domain of human adenovirus type 48 fiber. Human Gene Therapy 22(10), pp. A128-A128.
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes. Journal of Virology 85(20), pp. 10914-10919. (10.1128/JVI.05382-11)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus:FX complexes [Abstract]. Human Gene Therapy 22(10), pp. A34-A34. (10.1089/hum.2011.2525)
- Kitahara, H. et al. 2011. COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78. Molecular Cancer Research 9(6), pp. 688-701. (10.1158/1541-7786.MCR-10-0470)
2010
- Othman, M. et al. 2010. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 116(18), pp. 3645-3652. (10.1182/blood-2009-12-261131)
- Alba, R. et al. 2010. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116(15), pp. 2656-2664. (10.1182/blood-2009-12-260026)
- Bradshaw, A. C. et al. 2010. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. Plos Pathogens 6(10), article number: e1001142. (10.1371/journal.ppat.1001142)
- Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A. and Baker, A. H. 2010. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10), pp. 2290-2355. (10.3390/v2102290)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the factor X serine protease domain ablates heparan sulfate proteoglycan engagement by Ad5-FX complexes. Human Gene Therapy 21(9), pp. 1187-1187. (10.1089/hum.2010.804)
- Collins, L., Parker, A. L., Gehman, J. D., Eckley, L., Perugini, M. A., Separovic, F. and Fabre, J. W. 2010. Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol. ACS Nano 4(5), pp. 2856-2864. (10.1021/nn901414q)
- Parker, A. L., Alba, R., Barouch, D. H., Delles, C. and Baker, A. H. 2010. In vitro evaluation of hexon modifications on the capacity of Ad5 to evade neutralising antibodies. Human Gene Therapy 21(4), pp. 518-518. (10.1089/hum.2010.1225)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the FX serine protease domain ablates HSGP engagment by Ad5/FX complexes. Human Gene Therapy 21(4), pp. 512-513. (10.1089/hum.2010.1225)
- Alba, R. et al. 2010. Biodistribution and inflammatory profiles of hepatocyte-detargeted FX-binding ablated Ad5 vectors. Human Gene Therapy 21(4), pp. 498-499. (10.1089/hum.2010.1224)
2009
- Greig, J. A. et al. 2009. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular Therapy 17(10), pp. 1683-1691. (10.1038/mt.2009.152)
- Alba, R. et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114(5), pp. 965-971. (10.1182/blood-2009-03-208835)
- Greig, J. A. et al. 2009. Influence of factor X on in vitro and in vivo gene delivery by Ad5 and Ad35 vectors. Molecular Therapy 17, pp. S325-S325.
- Parker, A. L. et al. 2009. Genome wide and micro RNA profiling of murine livers following acute phase intravenous delivery of Ad5 reveals subsets of hepatocyte and kupffer cell regulated genes. Molecular Therapy 17, pp. S43-S44.
- Alba, R. et al. 2009. Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo. Molecular Therapy 17, pp. S6-S6.
- Parker, A. et al. 2009. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. Journal of Virology 83(1), pp. 479-483. (10.1128/JVI.01878-08)
2008
- Parker, A., Nicklin, S. A. and Baker, A. H. 2008. Interactions of adenovirus vectors with blood: Implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics 10(5), pp. 439-448.
- Waddington, S. N. et al. 2008. A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy 19(4), pp. 409-409. (10.1089/hum.2008.1327)
- Parker, A. et al. 2008. An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy 19(4), pp. 407-407. (10.1089/hum.2008.1327)
- Greig, J. A. et al. 2008. Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35. Human Gene Therapy 19(4), pp. 398-398.
- Waddington, S. N. et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3), pp. 397-409. (10.1016/j.cell.2008.01.016)
- Kubo, N., Akita, N., Shimizu, A., Kitahara, H., Parker, A. L. and Miyagawa, S. 2008. Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting 16(5), pp. 396-404. (10.1080/10611860802088796)
2007
- Waddington, S. N., Parker, A. L., Havenga, M., Nicklin, S. A., Buckley, S. M. K., McVey, J. H. and Baker, A. H. 2007. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology 81(17), pp. 9568-9571. (10.1128/JVI.00663-07)
- Parker, A. L., Eckley, L., Singh, S., Preece, J. A., Collins, L. and Fabre, J. W. 2007. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1770(9), pp. 1331-1337. (10.1016/j.bbagen.2007.06.009)
- Parker, A. L. et al. 2007. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology 81(7), pp. 3627-3631. (10.1128/JVI.02786-06)
- Maruta, F. et al. 2007. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting 15(4), pp. 311-319. (10.1080/10611860701195510)
2006
- Akita, N. et al. 2006. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Science 97(10), pp. 1075-1081. (10.1111/j.1349-7006.2006.00291.x)
- Parker, A. L. et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108(8), pp. 2554-2561. (10.1182/blood-2006-04-008532)
- Parker, A. L. et al. 2006. Hepatic tropism of adenoviral type 5 vectors can be mediated by multiple coagulation factors. Molecular Therapy 13(S1), pp. S143-S143. (10.1016/j.ymthe.2006.08.436)
- Shimizu, A. et al. 2006. Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology 71(1-2), pp. 136-145. (10.1159/000100479)
2005
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2005. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. Journal of Gene Medicine 7(12), pp. 1545-1554. (10.1002/jgm.809)
- Read, M. L., Spice, R., Parker, A. L., Mir, S. and Logan, A. 2005. 12th Annual Congress of the European Society of Gene Therapy. Expert Opinion on Biological Therapy 5(1), pp. 137-141. (10.1517/14712598.5.1.137)
- Parker, A. L., Fisher, K. D., Oupicky, D., Read, M. L., Nicklin, S. A., Baker, A. H. and Seymour, L. W. 2005. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting 13(1), pp. 39-51. (10.1080/10611860400020449)
2004
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2004. Free and (Lys)(16) containing fusogenic peptides for non-viral gene delivery to dividing and post mitotic cells. Journal of Gene Medicine 6(9), pp. S13-S13.
- Parker, A. L., Newman, C., Briggs, S., Seymour, L. and Sheridan, P. J. 2004. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Reviews in Molecular Medicine 5, pp. 1-15. (10.1017/S1462399403006562)
2003
- Maruta, F., Parker, A. L., Fisher, K. D., Murray, P. G., Kerr, D. J. and Seymour, L. W. 2003. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. Journal of Drug Targeting 11(1), pp. 53-59.
2002
- Parker, A. L. and Seymour, L. W. 2002. Targeting of polyelectrolyte RNA complexes to cell surface integrins as an efficient cytoplasmic transfection mechanism. Journal of Bioactive and Compatible Polymers 17(4), pp. 229-238. (10.1106/088391102027977)
- Maruta, F. et al. 2002. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy 9(6), pp. 543-552. (10.1038/sj.cgt.7700470)
- Parker, A. L., Oupicky, D., Dash, P. R. and Seymour, L. W. 2002. Methodologies for monitoring, nanoparticle formation by self-assembly of DNA with poly(L-lysine). Analytical Biochemistry 302(1), pp. 75-80. (10.1006/abio.2001.5507)
- Oupicky, D., Parker, A. L. and Seymour, L. W. 2002. Laterally stabilized complexes of DNA with linear reducible polycations: Strategy for triggered intracellular activation of DNA delivery vectors. Journal of the American Chemical Society 124(1), pp. 8-9. (10.1021/ja016440n)
2000
- Carlisle, R. C., Fisher, K. D., Parker, A. L. and Seymour, L. W. 2000. Systems for gene delivery based on combination of viral and non-viral vectors. Targeting of Drugs 323, pp. 117-125.
Articles
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Preston, H. E., Bayliss, R., Temperton, N., Neto, M. M., Brewer, J. and Parker, A. L. 2023. Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation. iScience 26(9), article number: 107567. (10.1016/j.isci.2023.107567)
- Lovatt, C. and Parker, A. L. 2023. Oncolytic viruses and immune checkpoint inhibitors: the "hot" new power couple. Cancers 15(16), article number: 4178. (10.3390/cancers15164178)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
- Othman, M. et al. 2023. Corrigendum to To clot or not to clot? Ad is the question?Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia [J Thromb Haemost. 2021 Nov;19(11):2845-2856. doi: 10.1111/jth.15485]. Journal of Thrombosis and Haemostasis (10.1016/j.jtha.2023.01.022)
- Swift, E. A., Pollard, S. M. and Parker, A. L. 2022. Engineering cancer selective virotherapies: are the pieces of the puzzle falling into place?. Human Gene Therapy 33(21-22) (10.1089/hum.2022.178)
- Cunliffe, T. G., Parker, A. L. and Jaramillo, A. 2022. Pseudotyping bacteriophage P2 tail fibers to extend the host range for biomedical applications. ACS Synthetic Biology 11(10), pp. 3207-3215. (10.1021/acssynbio.1c00629)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Toh, C., Wang, G. and Parker, A. L. 2022. The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. Clinical Medicine 22(2), pp. 140-144. (10.7861/clinmed.2022-0006)
- Tate, S. J., Van de Sande, L., Ceelen, W. P., Torkington, J. and Parker, A. L. 2021. The feasibility of Pressurised Intraperitoneal Aerosolised Virotherapy (PIPAV) to administer oncolytic adenoviruses. Pharmaceutics 13(12), article number: 2043. (10.3390/pharmaceutics13122043)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Othman, M. et al. 2021. To clot or not to clot? Ad is the question - insights on mechanisms related to vaccine induced thrombotic thrombocytopenia. Journal of Thrombosis and Haemostasis 19(11), pp. 2845-2856. (10.1111/jth.15485)
- Nestic, D., Bozinovic, K., Pehar, I., Wallace, R., Parker, A. L. and Majhen, D. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163(4), pp. 389-398. (10.1111/imm.13323)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Davies, J. A. et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13(5), article number: 864. (10.3390/v13050864)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
- Wongthida, P. et al. 2020. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology 22(12), pp. 1757-1770. (10.1093/neuonc/noaa126)
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
- Mowbray, N. G. et al. 2020. Safe management of surgical smoke in the age of COVID-19. British Journal of Surgery 107(11), pp. 1406-1413. (10.1002/bjs.11679)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- Crowther, M. D. et al. 2020. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology 21, pp. 178 - 185. (10.1038/s41590-019-0578-8)
- Man, S., Foster, J., Carapuca, E., Davies, J. A., Parker, A., Sosabowski, J. and Hallden, G. 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9, article number: 12840. (10.1038/s41598-019-49150-9)
- Baker, A., Mundy, R. M., Davies, J. A., Rizkallah, P. and Parker, A. L. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5(9), article number: eaax3567. (10.1126/sciadv.aax3567)
- Baker, A. T. et al. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10, article number: 741. (10.1038/s41467-019-08599-y)
- Uusi-Kerttula, H. et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24(17), pp. 4215-4224. (10.1158/1078-0432.CCR-18-1089)
- Baker, A., Aguirre-Hernández, C., Halldén, G. and Parker, A. 2018. Designer oncolytic adenovirus: coming of age. Cancers 10(6), article number: 201. (10.3390/cancers10060201)
- Hulin-Curtis, S., Davies, J. A., Jones, R., Hudson, E., Hanna, L., Chester, J. D. and Parker, A. L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9(41), pp. 26328-26341. (10.18632/oncotarget.25242)
- Man, Y. K. S. et al. 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17(2), pp. 575-587. (10.1158/1535-7163.MCT-17-0671)
- Uusi-Kerttula, H. and Parker, A. L. 2018. Precision virotherapies: Coming soon. Oncotarget 9(86) (10.18632/oncotarget.26280)
- Yan, B., Wang, Z., Parker, A., Lai, Y., Thomas, J. P., Yue, L. and Monks, J. N. 2017. Superlensing microscope objective lens. Applied Optics 56(11), pp. 3142-3147. (10.1364/AO.56.003142)
- Robertson, S., Alba, R., Duffy, M. R., Clarke, C., Parker, A. L., Nicklin, S. A. and Baker, A. H. 2016. Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology 97(8), pp. 1911-1916. (10.1099/jgv.0.000505)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Hanna, L., Chester, J. D. and Parker, A. L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23(7), pp. 229-234. (10.1038/cgt.2016.22)
- Uusi-Kerttula, H., Davies, J., Curtis, S., Chester, J. and Parker, A. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7(19), pp. 27926-27937. (10.18632/oncotarget.8545)
- Uusi-Kerttula, H., Hulin-Curtis, S., Davies, J. A. and Parker, A. L. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7(11), pp. 6009-6042. (10.3390/v7112923)
- Uusi-Kerttula, H., Davies, J. A., Coughlan, L., Chester, J. D., Parker, A. L. and Parker, A. L. 2015. Incorporation of avß6 integrin-targeting peptide into chimaeric Ad5/fibre knob 48 vector results in efficient tumour-targeting and evasion of neutralisation in clinical ascites. Human Gene Therapy 26(10), pp. A93-A93., article number: P224. (10.1089/hum.2015.29008.abstracts)
- Uusi-Kerttula, H., Davies, J., Coughlan, L., Jones, R., Chester, J. D. and Parker, A. L. 2015. Development of an Ad5 vector pseudotyped with Ad48 knob protein and targeted to αvβ6 integrin efficiently targets tumour cells and evades pre-existing immunity in clinical ascites. Human Gene Therapy 26(9), pp. A33-A33., article number: PO71. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Modulation of Ad5 fibre knob as a means of circumventing pre-existing immunity in clinical ovarian ascites. Human Gene Therapy 26(9), pp. A23-A23., article number: PO39. (10.1089/hum.2015.29005.abstracts)
- Hulin-Curtis, S., Uusi-Kerttula, H., Jones, R., Baker, A., Chester, J. D. and Parker, A. L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26(9), pp. A33-A34., article number: PO72. (10.1089/hum.2015.29005.abstracts)
- Uusi-Kerttula, H. et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26(5), pp. 320-329. (10.1089/hum.2015.015)
- Dakin, R. S., Parker, A. L., Delles, C., Nicklin, S. A. and Baker, A. H. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy 26(5), pp. 312-319. (10.1089/hum.2015.019)
- Nivsarkar, M. S. et al. 2015. Evidence for contribution of CD4+CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery. Journal of Immunology Research 2015, article number: 397879. (10.1155/2015/397879)
- Guinn, B., Braidwood, L., Parker, A., Peng, K. and Seymour, L. 2014. 8th international conference on oncolytic virus therapeutics. Human Gene Therapy 25(12), pp. 1062-1084. (10.1089/hum.2014.118)
- Dakin, R. S., Parker, A., Ma, J., Custers, J., Nicklin, S. A. and Baker, A. H. 2014. Efficient gene transfer to human vascular cells in vitro and ex vivo using adenovirus serotype 49. Cardiovascular Research 103(suppl), pp. S42. (10.1093/cvr/cvu082.170)
- Coughlan, L., Uusi-Kerttula, H., Ma, J., Degg, B. P., Parker, A. L. and Baker, A. H. 2014. Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation. Human Gene Therapy 25(4), pp. 385-394. (10.1089/hum.2014.016)
- Parker, A. L., White, K. M., Lavery, C. A., Custers, J., Waddington, S. N. and Baker, A. H. 2013. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Therapy 20(12), pp. 1158-1164. (10.1038/gt.2013.44)
- White, K. M. et al. 2013. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. Journal of Cardiothoracic Surgery 8(1), article number: 183. (10.1186/1749-8090-8-183)
- Kaur, H., Toukh, M., Corscadden, K., Parker, A. L. and Othman, M. 2013. Fucoidan improves adenovirus mediated thrombocytopenia and enhances viral liver transduction [Abstract]. Journal of Thrombosis and Haemostatis 11(S1), pp. 451-452. (10.1111/jth.12284)
- Duffy, M. R., Parker, A. L., Kalkman, E. R., White, K., Kovalskyy, D., Kelly, S. M. and Baker, A. H. 2013. Identification of novel small molecule inhibitors of adenovirus gene transfer using a high throughput screening approach. Journal of Controlled Release 170(1), pp. 132-140. (10.1016/j.jconrel.2013.05.007)
- Coughlan, L. et al. 2012. Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy 20(12), pp. 2268-2281. (10.1038/mt.2012.162)
- Duffy, M. R., Parker, A. L., Bradshaw, A. C. and Baker, A. H. 2012. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine 7(2), pp. 271-288. (10.2217/nnm.11.186)
- Coughlan, L., Uusi-Kerttula, H., Degg, B., Parker, A. L., Custers, J., Nicklin, S. A. and Baker, A. H. 2011. In vitro assessment of targeting peptide incorporation within the knob domain of human adenovirus type 48 fiber. Human Gene Therapy 22(10), pp. A128-A128.
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A Cluster of Basic Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of Adenovirus/FX Complexes. Journal of Virology 85(20), pp. 10914-10919. (10.1128/JVI.05382-11)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H. and Baker, A. H. 2011. A cluster of basic amino acids in the factor X serine protease mediate surface attachment of adenovirus:FX complexes [Abstract]. Human Gene Therapy 22(10), pp. A34-A34. (10.1089/hum.2011.2525)
- Kitahara, H. et al. 2011. COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78. Molecular Cancer Research 9(6), pp. 688-701. (10.1158/1541-7786.MCR-10-0470)
- Othman, M. et al. 2010. Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. Blood 116(18), pp. 3645-3652. (10.1182/blood-2009-12-261131)
- Alba, R. et al. 2010. Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116(15), pp. 2656-2664. (10.1182/blood-2009-12-260026)
- Bradshaw, A. C. et al. 2010. Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. Plos Pathogens 6(10), article number: e1001142. (10.1371/journal.ppat.1001142)
- Coughlan, L., Alba, R., Parker, A. L., Bradshaw, A. C., McNeish, I. A., Nicklin, S. A. and Baker, A. H. 2010. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2(10), pp. 2290-2355. (10.3390/v2102290)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the factor X serine protease domain ablates heparan sulfate proteoglycan engagement by Ad5-FX complexes. Human Gene Therapy 21(9), pp. 1187-1187. (10.1089/hum.2010.804)
- Collins, L., Parker, A. L., Gehman, J. D., Eckley, L., Perugini, M. A., Separovic, F. and Fabre, J. W. 2010. Self-assembly of peptides into spherical nanoparticles for delivery of hydrophilic moieties to the cytosol. ACS Nano 4(5), pp. 2856-2864. (10.1021/nn901414q)
- Parker, A. L., Alba, R., Barouch, D. H., Delles, C. and Baker, A. H. 2010. In vitro evaluation of hexon modifications on the capacity of Ad5 to evade neutralising antibodies. Human Gene Therapy 21(4), pp. 518-518. (10.1089/hum.2010.1225)
- Duffy, M. R., Bradshaw, A. C., Parker, A. L., Nicklin, S. A., McVey, J. H. and Baker, A. H. 2010. Modification of the FX serine protease domain ablates HSGP engagment by Ad5/FX complexes. Human Gene Therapy 21(4), pp. 512-513. (10.1089/hum.2010.1225)
- Alba, R. et al. 2010. Biodistribution and inflammatory profiles of hepatocyte-detargeted FX-binding ablated Ad5 vectors. Human Gene Therapy 21(4), pp. 498-499. (10.1089/hum.2010.1224)
- Greig, J. A. et al. 2009. Influence of coagulation factor X on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Molecular Therapy 17(10), pp. 1683-1691. (10.1038/mt.2009.152)
- Alba, R. et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114(5), pp. 965-971. (10.1182/blood-2009-03-208835)
- Greig, J. A. et al. 2009. Influence of factor X on in vitro and in vivo gene delivery by Ad5 and Ad35 vectors. Molecular Therapy 17, pp. S325-S325.
- Parker, A. L. et al. 2009. Genome wide and micro RNA profiling of murine livers following acute phase intravenous delivery of Ad5 reveals subsets of hepatocyte and kupffer cell regulated genes. Molecular Therapy 17, pp. S43-S44.
- Alba, R. et al. 2009. Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo. Molecular Therapy 17, pp. S6-S6.
- Parker, A. et al. 2009. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. Journal of Virology 83(1), pp. 479-483. (10.1128/JVI.01878-08)
- Parker, A., Nicklin, S. A. and Baker, A. H. 2008. Interactions of adenovirus vectors with blood: Implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics 10(5), pp. 439-448.
- Waddington, S. N. et al. 2008. A critical role for the adenovirus serotype 5 hexon in liver gene transfer. Human Gene Therapy 19(4), pp. 409-409. (10.1089/hum.2008.1327)
- Parker, A. et al. 2008. An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy 19(4), pp. 407-407. (10.1089/hum.2008.1327)
- Greig, J. A. et al. 2008. Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35. Human Gene Therapy 19(4), pp. 398-398.
- Waddington, S. N. et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3), pp. 397-409. (10.1016/j.cell.2008.01.016)
- Kubo, N., Akita, N., Shimizu, A., Kitahara, H., Parker, A. L. and Miyagawa, S. 2008. Identification of oligopeptide binding to colon cancer cells separated from patients using laser capture microdissection. Journal of Drug Targeting 16(5), pp. 396-404. (10.1080/10611860802088796)
- Waddington, S. N., Parker, A. L., Havenga, M., Nicklin, S. A., Buckley, S. M. K., McVey, J. H. and Baker, A. H. 2007. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology 81(17), pp. 9568-9571. (10.1128/JVI.00663-07)
- Parker, A. L., Eckley, L., Singh, S., Preece, J. A., Collins, L. and Fabre, J. W. 2007. (LYS)(16)-based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1770(9), pp. 1331-1337. (10.1016/j.bbagen.2007.06.009)
- Parker, A. L. et al. 2007. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology 81(7), pp. 3627-3631. (10.1128/JVI.02786-06)
- Maruta, F. et al. 2007. Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting 15(4), pp. 311-319. (10.1080/10611860701195510)
- Akita, N. et al. 2006. Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Science 97(10), pp. 1075-1081. (10.1111/j.1349-7006.2006.00291.x)
- Parker, A. L. et al. 2006. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108(8), pp. 2554-2561. (10.1182/blood-2006-04-008532)
- Parker, A. L. et al. 2006. Hepatic tropism of adenoviral type 5 vectors can be mediated by multiple coagulation factors. Molecular Therapy 13(S1), pp. S143-S143. (10.1016/j.ymthe.2006.08.436)
- Shimizu, A. et al. 2006. Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology 71(1-2), pp. 136-145. (10.1159/000100479)
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2005. Exploration of peptide motifs for potent non-viral gene delivery highly selective for dividing cells. Journal of Gene Medicine 7(12), pp. 1545-1554. (10.1002/jgm.809)
- Read, M. L., Spice, R., Parker, A. L., Mir, S. and Logan, A. 2005. 12th Annual Congress of the European Society of Gene Therapy. Expert Opinion on Biological Therapy 5(1), pp. 137-141. (10.1517/14712598.5.1.137)
- Parker, A. L., Fisher, K. D., Oupicky, D., Read, M. L., Nicklin, S. A., Baker, A. H. and Seymour, L. W. 2005. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting 13(1), pp. 39-51. (10.1080/10611860400020449)
- Parker, A. L., Collins, L., Zhang, X. H. and Fabre, J. W. 2004. Free and (Lys)(16) containing fusogenic peptides for non-viral gene delivery to dividing and post mitotic cells. Journal of Gene Medicine 6(9), pp. S13-S13.
- Parker, A. L., Newman, C., Briggs, S., Seymour, L. and Sheridan, P. J. 2004. Nonviral gene delivery: techniques and implications for molecular medicine. Expert Reviews in Molecular Medicine 5, pp. 1-15. (10.1017/S1462399403006562)
- Maruta, F., Parker, A. L., Fisher, K. D., Murray, P. G., Kerr, D. J. and Seymour, L. W. 2003. Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. Journal of Drug Targeting 11(1), pp. 53-59.
- Parker, A. L. and Seymour, L. W. 2002. Targeting of polyelectrolyte RNA complexes to cell surface integrins as an efficient cytoplasmic transfection mechanism. Journal of Bioactive and Compatible Polymers 17(4), pp. 229-238. (10.1106/088391102027977)
- Maruta, F. et al. 2002. Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy 9(6), pp. 543-552. (10.1038/sj.cgt.7700470)
- Parker, A. L., Oupicky, D., Dash, P. R. and Seymour, L. W. 2002. Methodologies for monitoring, nanoparticle formation by self-assembly of DNA with poly(L-lysine). Analytical Biochemistry 302(1), pp. 75-80. (10.1006/abio.2001.5507)
- Oupicky, D., Parker, A. L. and Seymour, L. W. 2002. Laterally stabilized complexes of DNA with linear reducible polycations: Strategy for triggered intracellular activation of DNA delivery vectors. Journal of the American Chemical Society 124(1), pp. 8-9. (10.1021/ja016440n)
- Carlisle, R. C., Fisher, K. D., Parker, A. L. and Seymour, L. W. 2000. Systems for gene delivery based on combination of viral and non-viral vectors. Targeting of Drugs 323, pp. 117-125.
Book sections
- Parker, A. L., Bradshaw, A. C., Alba, R., Nicklin, S. A. and Baker, A. H. 2013. Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. eds. Adenovirus., Vol. 1089. Methods in Molecular Biology Humana Press, pp. 45-59., (10.1007/978-1-62703-679-5_3)
Websites
- Baker, A. T., Mundy, R., Davies, J., Rizkillah, P. T. and Parker, A. L. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. [Online]. bioRxiv. (10.1101/580076) Available at: https://doi.org/10.1101/580076
Research
Adenovirus Virology
Research within the Parker laboratory is focussed on developing bespoke oncolytic adenoviral vectors for translational cancer applications. To achieve this, we are developing tumour selective virotherapies that selectively infect cancer cells, leaving normal cells uninfected. To achieve this, we take two approaches. Our first approach is a “bottom up” approach involving the use of Ad5, a well described, well understood and clinically well studied virus. Although safe, Ad5 has a number of features which limits efficacy as a tumour selective virotherapy.
Firstly, the primary Ad5 receptor, hCAR (human coxsackie and adenovirus receptor) is ubiquitously expressed on red blood cells and in all tissues, located at tight junctions, but is commonly downregulated or even absent in advanced cancers, and therefore represents a poor target for tumour targeting strategies.
Secondly, uptake into immune cells, mediated by the interaction between αvβ3/5 integrin and the Ad5 penton base protein can promote significant dose limiting toxicities.
Finally, intravascular delivery of Ad5, a pre-requisite for therapy of metastatic disease, is compromised for Ad5 due to the high affinity interaction with the blood clotting factor, FX, which bridges the virus: FX complex to HSPGs and is responsible for the significant levels of hepatic uptake of Ad5 based virotherapies (overviewed in figure 1). To target the refined, basal vector to tumour cells, we further modulate the vector to incorporate peptide ligands binding to tumour specific markers, such as αvβ6 integrin (figure 2).
Our second approach represents a “top down” approach. Ad5 represents just one of a diverse family of viruses, presently numbering 57 serotypes, spanning 7 species (A-G). Many of these viruses have unique tropisms, mediated through interactions with as yet undocumented receptors. Furthermore, many of these alternative Ad serotypes are rarely isolated and therefore have very limited levels of pre-existing immunity in the general population, which is likely to be advantageous when using them clinically.
We are exploring the natural diversity of Ad tropism by seeking to develop vectors based on rarely isolated Ads from species B and D. We investigate potential receptor interactions at the molecular level by resolving the structure of the major tropism determining epitopes in super-high resolution by X-ray diffraction, and biologically by using sophisticated molecular techniques to generate chimeric viral vectors. Our recent Nature Communcations paper on species D structure and function (which can be access here http://dx.doi.org/10.1038/s41467-019-08599-y) was recently featured in several news outlets and was covered in a press release (http://www.cardiff.ac.uk/news/view/1442255-seeing-the-unseeable)
Our research on targeted virotherapies was recently featured online on the BBC news website:
http://www.bbc.co.uk/news/uk-wales-south-east-wales-40305580
https://www.bbc.co.uk/news/uk-wales-44237820
As well as featuring on BBC Wales today:
In the below link, we describe our recently funded CRUK project, developing adenoviral based virotherapies that are “trained” to fight ovarian cancer:
https://www.youtube.com/watch?v=DDQPpZHZbo0&t=12s
Our research was also highlighted in a recent (Autumn 2017) edition of Advances Wales (p12)
Our collaborative research with Gunnel Hallden (Bart's Cancer Institute) on targeted virotherapies for pancreatic cancer was subject of some significant press coverage - and we look forward to extending this exciting translational collaboration further!
http://www.cardiff.ac.uk/news/view/1083809-inhibiting-the-growth-of-pancreatic-cancer
Teaching
I perform a wide range of teaching engagements for the University, as well as a significant teaching and engagement for the wider community. Specifically, within Cardiff university I:
- Design and perform Student Selected Components (SSCs) for undergraduate medical students.
- Run tutorials for medical students on how to critically review scientific papers.
- Perform virology tutorials and lectures as part of the undergraduate programme.
- Act as a personal tutor to undergraduate medical students.
- Act as PhD panel appraiser for >10 PhD students within the Divisions of Cancer and Genetics and Division of Infection and Immunity.
- Supervise undergraduate research projects.
- Supervise ERASMUS student projects.
- Supervise PTY student projects.
- Act as an assessor for undergraduate research projects.
- Act as a personal mentor for 7 PhD students across the Divisions of Cancer and Genetics and Infection and Immunity.
- Regularly acting as a PhD panel member for PhD student vivas (presently 6 times as an external examiner, 3 times as an internal examiner and 13 times as viva chair).
Biography
My interest in gene and cell therapy began whilst studying for my undergraduate degree in Genetics (University of Sheffield), which inspired me to pursue a PhD in this field. My PhD was performed under the supervision of Prof Len Seymour (now at the University of Oxford) at the CRUK Institute for Cancer Studies at the University of Birmingham, and I completed my thesis entitled "Development of Peptide Targeted Gene Delivery Systems" in 2003.
My first postdoctoral position was under the supervision of Prof John Fabre, where I developed novel bioresponse peptide systems for local gene delivery (2003-2005) and I published several articles from this post. Whilst in this position I also developed and patented a versatile, highly organised form of nanoparticle for rapid, targetable delivery of drugs or mRNA/miRNAs into the cytoplasm of target cells (Collins L, Parker AL et al, ACS Nano, 2010).
My desire to work on viral vectors for gene and cell therapy applications resulting in my relocating to Glasgow University from 2005-2013, where I made important contributions to how Adenoviral (Ad) based vectors interact with host cells and proteins, and how these interactions dictate viral tropism and toxicity. In 2007 I was awarded a prestigious RSE Personal Fellowship to generate safer and more efficacious Ad based vectors for in vivo applications. In 2010-2013 I was a BHF funded Senior Scientist. During this period I published a number of high impact articles (Cell, Blood, PLoS pathogens, Molecular Therapy, Journal of Virology), and patented the use of a novel Ad serotype for gene therapy applications.
In 2013 my desire to apply my adenoviral knowledge in the cancer setting resulted in my relocation to Cardiff University as a Lecturer and group leader. In 2014 I was promoted to Senior Lecturer, the to Reader in 2018, and to Professor of Translational Virotherapies in 2020. Since 2020 I lead the targeted therapeutic programme of the HCRW funded Wales Cancer Research Centre (https://www.walescancerresearchcentre.org/wcrc/). I have been an elected board member of the British Society for Gene and Cell Therapy (https://www.bsgct.org/) since 2014, and have been Treasurer for the society since 2020.
I am fortunate to lead a expanding and hugely talented group of dedicated individuals within the Division of Cancer and Genetics, where we are progressing next generation "precision immunovirotherpies" towards the clinic, underpinned by fanstatic support from our major funders, Cancer Research UK, Cance Research Wales, Tenovus Cancer Care, Health and Care Research Wales and KESS 2.
Honours and awards
- Programme lead for the Wales Cancer Research Centre: Targeted Therapeutics (2020-2025)
- Treasurer of the British Society for Gene and Cell Therapy (2020-2024)
- Organiser and chair of the local organising committee for the 14th Annual Meeting of the British Society for Gene and Cell Therapy (Cardiff, April 2017)
- Participant in Welsh Crucible 2015.
- Elected BSGCT Board member (2014-2017, re-elected in 2017-2020), where I established and chair the Early Career Development and Collaboration subcommittee and play an active role as a member of the communication and promotion subcommittee.
- Awarded 2006 “Excellence in Research Award” by the American Society for Gene and Cell therapy for my research on adenoviral vectors and their interactions with coagulation factors.
- Runner up, NEXXUS “Young Biomedical Researcher of the Year” category 2007.
- Awarded highly competitive Royal Society of Edinburgh Fellowship in the Biomedical Sciences (2007-2010) to develop adenoviral vectors devoid of coagulation factor interactions for in vivo applications.
- Travel Grant Awardee, American Society of Gene and Cell Therapy, 2006 & 2008.
- Grant committee member - NC3Rs.
- Grant reviewer for MRC, Worldwide Cancer Research, the French National Research Agency, Fonds de recherche du Québec – Santé and Wellbeing of Women.
- Regular manuscript reviewer for a range of high impact journals.
- BSGCT session chair 2012, 2014, 2016, 2017.
- Editorial board – Chemotherapy journal.
- Abstract reviewer for BSGCT, ASGCT and ESGCT.
Professional memberships
- Founding member of the British Society for Gene and Cell Therapy (2003-), elected board member (2014-17), chair of the Early Career Development and Collaboration subcommittee, vice chair of the Membership and Awareness subcommittee, and memeber of the Public Engagement subcommittee.
- Associate Member of the American Society of Gene and Cell Therapy (2003-), and I have written lay patient orientation perspectives for the ASGCT website on recent developments in the gene therapy field.
- Member of the Microbiology Society (formerly the Society for General Microbiology)
- I am a registered STEMNET ambassador, and as such I devote my own time to outreach activities in local schools seeking to inspire new generations of children into science. I also perform a significant engagement activities with local patient support groups and charities. My engagement activities are significant enough to have formed the basis for a case report by Cardiff University School of Medicine.
Academic positions
August 2020 - Present: Professor of Translational Virotherapies, Cardiff University School of Medicine.
August 2018 - July 2020: Reader in Translational Virotherapies, Cardiff University School of Medicine.
August 2014 - July 2018: Senior Lecturer in Translational Oncology, Cardiff University School of Medicine.
February 2013 - July 2014: Lecturer in Translational Oncology, Cardiff University School of Medicine.
October 2010 – January 2013: BHF Senior Scientist, BHF Glasgow Cardiovascular Research Centre (GCRC), University of Glasgow.
October 2007 – September 2010: Royal Society of Edinburgh Fellow in the Biomedical Sciences, BHF Glasgow Cardiovascular Research Centre (GCRC), University of Glasgow.
September 2005 – September 2007: Research Associate BHF Glasgow Cardiovascular Research Centre (GCRC), University of Glasgow.
August 2003 – August 2005: Research Associate, King’s College London (Department of Clinical Sciences).
Committees and reviewing
Internal committees:
- 2017 - present: member of the DCG EDI committee
- 2015 – present: Seminar series organiser for the Institute of Cancer & Genetics, Cardiff University, UK.
- 2014 – present: GMBA committee member, College of Biomedical & Life Sciences, Cardiff University, UK.
- 2013 – present: Student Review Panel, Division of Cancer & Genetics and Division of Infection & Immunity, Cardiff University, UK.
- 2007 – 2013: Member of GM committee, Institute of Cardiovascular & Medical Sciences, Glasgow University, UK
- 2007 – 2013 Biological Safety Officer, Institute of Cardiovascular & Medical Sciences, Glasgow University, UK
External Committees
- National oversight group - cell and gene therapies in Wales
- 2015 - present: NC3Rs CrackIT review panel member
- Abstract committee reviewer for American Society for Gene and Cell Therapy
- Abstract committee reviewer for British Society for Gene and Cell Therapy
- Abstract committee reviewer for European Society for Gene and Cell Therapy
- Grant reviewer for MRC, Worldwide Cancer Research, the French National Research Agency, Fonds de recherche du Québec – Santé and Wellbeing of Women
Supervisions
My team is a thriving mix of fellows, postdoctoral staff, research students and technical staff. They are a pleasure to work with.
We are delighted to be working with Dr Carly Bliss since June 2020, who joins us as an independent research fellow (funded by Wellcome ISSF Research Fellowship funding), developing our viral platforms as vaccines for cancer and for infectious diseases.
The following postdoctoral researchers are presently employed in my group
- Dr Rebecca Bayliss (funded by Cancer Research UK).
- Dr Luned Badder (funded by Cancer Research Wales).
- Dr Mahulena Marsukova (funded by ECMC/WCRC)
- Dr Charley Lovatt (funded by NIHR)
- Dr Emily Bates (funded by ECMC)
The group is supported by two fantastic technical members of staff
- Mrs Joanne Jones.
- Dr Andy Robnson.
Within the group, I currently supervise to the following PhD/MD/Phil students
- Tabitha Cunliffe (funded by KESS2/Tenovus; co-supervised Prof Arwyn Jones (Pharmy) and Prof Alfonso Jaramillo (Warwick).
- Emily Bates (funded by Cardiff University School of Medicine; co-supervised by Prof John Chester).
- Alicia Teijeira-Crespo (funded by Cancer Research Wales; co-supervised my Prof Awen Gallimore & Prof Andy Godkin)
- Elise Moses (funded by ISSF Translational Kickstarter award/Velindre Charitable funds; co-supervised by Dr James Davies, Dr Richard Stanton, Dr Mererid Evans and Dr David Cole).
- Rebecca Wallace (funded by Cancer Research UK, co-supervised by Prof Awen Gallimore and Dr Carly Bliss).
- Emma Swift (funded by Cancer Research UK, co-supervised by Dr Pierre Rizkallah and Dr James Davies).
- Rosie Mundy (funded by GW4, co-supervised by Dr David Matthews (Bristol), Dr Carly Bliss and Dr Pierre Rizkallah).
- Adam Naskretski (part funded by South East Wales Gyncological fund, co-supervised by Toby Phesse, Sadie Jones and Rebecca Bayliss).
- Bethan Carter (WCAT).
I presently supervise the following undergraduate research projects
- James Thetford (PTY Student, Cardiff University): 5T4 as an adenoviral entry receptor
- Caitlin Dop (PTY student, Cardiff University): Design of universal coronavirus vaccines
I am interested in supervising PhD/MD students in following areas:
- Cancer virotherapies
- Drug delivery
- Vaccine development
- Gene Therapy
- Virology (with particular emphasis on adenoviral vectors)
- Virus: host interactions
- Immunotherapies
Combination therapies involving virotherapies (including radiotherapies, chemotherapies, immunotherapies, epigenetic therapies)
Current supervision
Emily Bates
Research student
Rosie Mundy
Research student
Rebecca Wallace
Research student
Emma Swift
Research student
Adam Naskretski
Research student
Alicia Teijeira Crespo
Research student
Engagement
I perform a significant amount of engagement activity on behalf of both School and for the British Society for Gene and Cell Therapy. I am a registered STEMNet ambassador, and regularly attend a variety of events including school outreach events to public and patient engagement events and science festivals, as well as writing lay blog articles on gene and cell therapy (see https://www.bsgct.org/author/alanparker/). My commitment to engagement has resulted in my featuring in a School of Medicine "Public Engagement and Involvement in Research" case study which can be accessed here https://www.cardiff.ac.uk/medicine/about-us/engagement/case-study-dr-alan-parker, and was also featured in the 2018 School of Medicine - Public Engagement and Involvement Annual Report, which can be accessed here https://www.cardiff.ac.uk/__data/assets/pdf_file/0010/1367875/Cardiff-University-School-of-Medicine-Public-Engagement-and-Involvement-Annual-Report-2017-18-.pdf
